The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review

Hartmann-Boyce, Jamie; Highton, Patrick; Rees, Karen; Onakpoya, Igho; Suklan, Jana; Curtis, Ffion; O'Mahoney, Lauren; Morris, Elizabeth; Kudlek, Laura; Morgan, Jessica; Lynch, Rosie; Marpadga, Sanjana; Seidu, Samuel; Khunti, Kamlesh

doi:10.1016/s2213-8587(23)00351-0

Cited by 7 publications

(2 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies reported that patients with DM have a higher risk of death and a higher probability of being hospitalized with Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) than those without diabetes [ 162 , 163 , 164 ]. A recent systematic review revealed that diabetic patients experienced worse clinical outcomes during the COVID-19 pandemic, with an increase in all-cause mortality and diabetes-related mortality; in particular, clinical outcomes worsened in women, children, and individuals of ethnic minorities [ 165 ].…”

Section: Resultsmentioning

confidence: 99%

View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences

Froldi

2024

Pharmaceuticals

View full text Add to dashboard Cite

Metformin is a synthetic biguanide used as an antidiabetic drug in type 2 diabetes mellitus, achieved by studying the bioactive metabolites of Galega officinalis L. It is also used off-label for various other diseases, such as subclinical diabetes, obesity, polycystic ovary syndrome, etc. In addition, metformin is proposed as an add-on therapy for several conditions, including autoimmune diseases, neurodegenerative diseases, and cancer. Although metformin has been used for many decades, it is still the subject of many pharmacodynamic and pharmacokinetic studies in light of its extensive use. Metformin acts at the mitochondrial level by inhibiting the respiratory chain, thus increasing the AMP/ATP ratio and, subsequently, activating the AMP-activated protein kinase. However, several other mechanisms have been proposed, including binding to presenilin enhancer 2, increasing GLP1 release, and modification of microRNA expression. Regarding its pharmacokinetics, after oral administration, metformin is absorbed, distributed, and eliminated, mainly through the renal route, using transporters for cationic solutes, since it exists as an ionic molecule at physiological pH. In this review, particular consideration has been paid to literature data from the last 10 years, deepening the study of clinical trials inherent to new uses of metformin, the differences in effectiveness and safety observed between the sexes, and the unwanted side effects. For this last objective, metformin safety was also evaluated using both VigiBase and EudraVigilance, respectively, the WHO and European databases of the reported adverse drug reactions, to assess the extent of metformin side effects in real-life use.

show abstract

Section: Resultsmentioning

confidence: 99%

View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences

Froldi

2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Disruptions in healthcare systems, changes in antimicrobial use patterns, and increased infection control measures have all contributed to shifts in the epidemiology of drug-resistant infections (5,8). Additionally, the focus on infection prevention and control during the pandemic may have in uenced the spread and transmission of drug-resistant pathogens in healthcare settings (9). The epidemiological trends of CRAB and CSAB from 2014 to 2023 revealed signi cant shifts in patterns, particularly during the COVID-19 pandemic.…”

Section: Discussionmentioning

confidence: 99%

Assessing the Impact of COVID-19 on the Epidemiology of Acinetobacter baumannii: A Longitudinal Study Spanning from 2014 to 2023

Zhang,

Lei,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Understanding the changes in the epidemiological characteristics of Acinetobacter baumannii before and after the COVID-19 pandemic may provide a scientific basis for clinical treatment and public health management. Methods Over a 10-year span from 2014 to 2023, a tertiary hospital in China separated A. baumannii isolated from patients according to whether it was carbapenem-resistant or carbapenem-sensitive. Information, such as sample type, drug sensitivities, MIC50, seasonal differences, and variances in patient sex, age, department, and outpatient and inpatient status, was examined. Results A total of 3,498 isolates of A. baumannii were assessed, including 1909 (54.6%) carbapenem-resistant A. baumannii (CRAB), 1501 (42.9%) carbapenem-sensitive A. baumannii (CSAB) isolates, and 88 (2.5%) carbapenem-intermediate A. baumannii isolates. Since the COVID-19 pandemic outbreak, the isolation rate of A. baumannii in outpatients had sharply decreased to 6.4%, while it had surged to 110% in inpatients. Simultaneously, the proportion of CRAB isolates had decreased to 67.3%, whereas that of CSAB isolates had increased to 150.8%. Notably, overall, the resistance rate of A. baumannii to 17 antibiotics decreased, with the most significant decreases in the combined sulfamethoxazole and amikacin, with decreases to 51.1% and 53.9%, respectively (p < 0.05). However there was an increase in the usage rate of moxifloxacin to 146.9%. The distribution proportion of CSAB in the third quarter was 0.6 times higher than that in the other three quarters, while the distribution of CRAB throughout the year was relatively balanced. Conclusions During the COVID-19 pandemic, significant changes occurred in people’s lifestyle. The notable decrease in the CRAB isolation rate highlights the effectiveness of strict isolation measures for controlling the transmission of drug-resistant bacteria in hospitals.

show abstract

Increased non‐COVID‐related death among people with diabetes during the COVID pandemic

Idris

2024

Diabetes Obesity and Metaboli

View full text Add to dashboard Cite

show abstract

The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review

Cited by 7 publications

References 134 publications

View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences

View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences

Assessing the Impact of COVID-19 on the Epidemiology of Acinetobacter baumannii: A Longitudinal Study Spanning from 2014 to 2023

Increased non‐COVID‐related death among people with diabetes during the COVID pandemic

Contact Info

Product

Resources

About